Aclarion presents on Nociscan technology at LSI Europe ’25

Aclarion (ACON) announced its recent presentation at LSI Europe ’25 which is now available to investors and stakeholders. During the presentation, CEO Brent Ness shared how Aclarion’s flagship platform, Nociscan, combines MR spectroscopy with augmented intelligence to provide objective, biomarker-based insights into discogenic pain. Key highlights include: Nociscan transforms MR spectroscopy signals into objective biomarker data, providing physicians insights to distinguish between painful and non-painful discs in the lumbar spine. This actionable information enables physicians to develop more personalized treatment plans for patients. The 300-patient CLARITY randomized clinical trial is designed to demonstrate that Nociscan-guided surgical decisioning can improve surgical outcomes for chronic low back pain beyond the current 54% industry success rate. Enrollment remains on track with internal interim results expected in Q2 2026. Recently strengthened balance sheet provides the capital needed to execute on commercial and clinical milestones. “LSI Europe brings together the world’s leading medtech investors and strategics,” said Brent Ness, CEO of Aclarion. “Our presentation details how Nociscan is uniquely positioned to transform the chronic low back pain market and drive shareholder value. We are pleased to make the replay available so investors can hear our growth story first-hand.”